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Abstract
 
Survivin has received great attention due to its expression in many human tumors and its po-
tential as a therapeutic target in cancer. Survivin expression has been described to be cell cycle–
dependent and restricted to the G
 
2
 
-M checkpoint, where it inhibits apoptosis in proliferating
cells. In agreement with this current view, we found that survivin expression was high in im-
mature neutrophils, which proliferate during differentiation. In contrast with immature cells,
mature neutrophils contained only little or no survivin protein. Strikingly, these cells reex-
pressed survivin upon granulocyte/macrophage colony-stimulating factor (CSF) or granulocyte
CSF stimulation in vitro and under inflammatory conditions in vivo. Moreover, survivin-defi-
cient mature neutrophils were unable to increase their lifespan after survival factor exposure.
Together, our findings demonstrate the following: (a) overexpression of survivin occurs in pri-
mary, even terminally differentiated cells and is not restricted to proliferating cells; and (b) sur-
vivin acts as an inhibitor of apoptosis protein in a cell cycle–independent manner. Therefore,
survivin plays distinct and independent roles in the maintenance of the G
 
2
 
-M checkpoint and
in apoptosis control, and its overexpression is not restricted to proliferating cells. These data
provide new insights into the regulation and function of survivin and have important implica-
tions for the pathogenesis, diagnosis, and treatment of inflammatory diseases and cancer.
Key words: antisense • cancer • cytokines • differentiation • infection
 
Introduction
 
Survivin is a member of the inhibitor of apoptosis protein
(IAP) family (1). Overexpression of survivin protects cells
from death induced by different apoptotic stimuli and, con-
versely, targeting survivin expression was shown to increase
apoptosis and chemosensitivity (2). However, the concept
that survivin is solely an antiapoptotic protein has recently
been challenged by findings in yeast and 
 
Caenorhabditis ele-
gans
 
, where it appears to act as a regulator of cell division
(3, 4). Early studies reported that survivin expression occurs
at the G
 
2
 
-M boundary of the cell cycle and interference
with its function leads to cell division defects, resulting in
multinucleated polyploid cells (5). More recent studies
have also shown that survivin shuttles between the nucleus
and the cytoplasm (6), where it effectively inhibits apopto-
sis, most likely by binding to second mitochondrial activa-
tor of caspase (Smac; reference 7), but not to caspases (8, 9).
Altogether, these data provide evidence that survivin acts as
a link between the apoptosis machinery and the check-
points that control mitotic progression. Thus, deregulated
expression of survivin has oncogenic potential by enabling
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cells to overcome the G
 
2
 
-M checkpoint and progress
through mitosis, and by providing cells with a mechanism
to evade checkpoint-controlled apoptosis.
Independent of its mode of action, survivin has garnered
great interest due to its differential pattern of tissue expres-
sion. Although fetal tissues abundantly express survivin
mRNA and protein, it has been reported to be absent
from most normal adult tissues. Interestingly, the majority
of human tumors express survivin protein at high levels,
suggesting that reactivation of the survivin gene occurs
frequently during carcinogenesis and malignant progres-
sion (10, 11). If indeed survivin inactivates Smac (7), its
overexpression in tumor cells might result in resistance to
a broad range of apoptotic stimuli, including chemo- and
radiation therapy. Based on these considerations, survivin
has been suggested as an attractive target for cancer therapy
(12).
In this paper, we demonstrate that survivin is highly ex-
pressed in immature neutrophils, whereas in mature neu-
trophils, survivin expression is absent or only marginal.
Strikingly, neutrophil hematopoietic growth factors reacti-
vated the survivin gene in these terminally differentiated
cells, which are unable to resume cell cycle progression at
G
 
2
 
-M, and high levels of survivin were expressed in mature
neutrophils under inflammatory conditions in vivo. Using
genetically modified mouse and human neutrophils, we
demonstrate that survivin has an exclusive antiapoptotic
function in these cells. Moreover, our data question the
value of survivin as a specific target for cancer therapy. In-
stead, survivin may be a new therapeutic target for the de-
velopment of antiinflammatory drugs.
 
Materials and Methods
 
Reagents. 
 
Human GM-CSF was purchased from Novartis
Pharma GmbH and human G-CSF was obtained from Aventis
Pharma AG. FITC-conjugated anti-CD14 and anti-CD15, allo-
phycocyanin-conjugated anti-CD34 and anti-CD11b, as well as
PE-conjugated anti-CD7, anti-CD16, and anti-CD36 mAbs
were obtained from Becton Dickinson and BD Biosciences.
From the same companies, we received nonconjugated anti-
CD15, anti–IAP-1, anti-XIAP, anti–Mcl-1, and anti–caspase-3
mAbs as well as mouse IL-3 and the annexin V apoptosis detec-
tion kit. Polyclonal rabbit antisurvivin, anti–IAP-2, and anti-
NAIP Abs were ordered from R&D Systems. Anti–
 
 
 
-actin mAb
was obtained from Sigma-Aldrich and anti–glyceraldehyde-3–
phosphate dehydrogenase (GAPDH) mAb was obtained from
Chemicon International, Inc. HRP-conjugated secondary Abs
were obtained from Amersham Biosciences. Rhodamine–tetra-
methyl rhodamine isothiocyanate (TRITC) and FITC-conjugated
goat anti–rabbit and donkey anti–mouse secondary Abs were
purchased from Jackson ImmunoResearch Laboratories. Anti-PE
secondary Ab microbeads were obtained from Miltenyi Biotec.
Myeloperoxidase (MPO) staining solution was provided by the
pharmacy of the University Hospital Bern. PHA was obtained
from Roche Diagnostics and anti-CD3 mAb was obtained from
DakoCytomation. All other chemicals were, unless stated other-
wise, obtained from Sigma-Aldrich.
The 20-mer first generation antisense oligonucleotide 4003
targeting the survivin mRNA has been described previously (13).
The second generation 2
 
 
 
-O-(2-methoxy)-ethyl-modified (2
 
 
 
-
MOE) gapmer version of 4003 (as) and its three-base mismatch
sequence control (ms) were synthesized using an automated
DNA synthesizer as described previously (model 394B; Applied
Biosystems; reference 14). Sequences were as follows: antisense
survivin, 5
 
 
 
-cscscsasgsCsCsTsTsCsCsAsGsCsTscscststsg-3
 
 
 
; and
mismatch survivin, 5
 
 
 
-cscstsasgsCsCsTsTsCsCsAsGsGsTscscst-
sasg-3
 
 
 
. Small letters refer to 2
 
 
 
-O-(2-methoxy)-ethyl-modified
nucleotides, capital letters to DNA, and “s” refers to phospho-
rothioate linkages.
 
Cells.
 
Bone marrow aspirates were obtained from cancer pa-
tients at staging or restaging and analyzed by an experienced he-
matologist. Only samples with normal cellular morphology and
distribution were considered in this work. The patients did not
receive any chemotherapeutic or immunosuppressive treatment
at the time of investigation. To induce sedimentation of the
erythrocytes, an equal volume of 2% dextran T-500 (Amersham
Biosciences) in 0.9% NaCl was added to the bone marrow aspi-
rates. The bone marrow leukocytes were layered on top of a
two-step discontinuous Percoll density gradient and centrifuged
at 1,000
 
 
 
g
 
 at 4
 
 
 
C for 20 min through which a mixed population
of immature neutrophils was obtained (15). Because this popula-
tion of cells also contained erythroid and lymphoid precursors,
we developed a new simple technique to improve the purity of
the immature neutrophil population based on negative selection.
The cells were incubated with a combination of anti-CD7 and
anti-CD36 mAbs and subsequently with secondary Ab micro-
beads. The labeled cells were depleted by passing them through a
magnetic cell separation system (Miltenyi Biotec) with LS
 
 
 
/VS
 
 
 
column in the field of a permanent magnet. The resulting cell
population contained 
 
 
 
97% cells of the neutrophil lineage as de-
termined by MPO staining (16), analysis of lineage-associated
surface proteins (17), as well as by staining with Diff-Quik (Me-
dion GmbH) and light microscopy.
Peripheral blood neutrophils were purified from healthy nor-
mal individuals or patients suffering from cystic fibrosis (CF) and
associated 
 
Pseudomonas aeruginosa
 
 infection by Ficoll-Hypaque
centrifugation (18, 19). The resulting cell populations contained
 
 
 
95% neutrophils. Written consent was obtained from all pa-
tients and control individuals who donated bone marrow aspi-
rates and blood, respectively. The study was approved by the lo-
cal ethics committee.
Peripheral blood neutrophils from heterozygous survivin
 
 
 
/
 
 
 
and normal survivin
 
 
 
/
 
 
 
 mice (20) were isolated by centrifugation
over a Histopaque 1119 and Histopaque 1077 gradient (Sigma-
Aldrich) using a standard protocol (21) 24 h after i.p. administra-
tion of 30 
 
 
 
g LPS. The purity of the resulting mouse neutrophil
population was between 82 and 85%. Blood samples of two mice
were pooled to obtain sufficient numbers of neutrophils to set up
one ex vivo viability experiment.
 
Characterization of Purified Bone Marrow Neutrophils. 
 
After pu-
rification, cells were stained with saturated concentrations of
fluorescence-labeled anti-CD7, anti-CD11b, anti-CD14, anti-
CD15, anti-CD16, anti-CD34, anti-CD36, and appropriate con-
trol mAbs according to standard protocols for flow cytometric
analysis (FACS Calibur™; Becton Dickinson). Based on the ex-
pression of lineage-associated surface proteins and light scattering
properties, bone marrow neutrophils were assigned to six distinct
maturational stages (17). The distribution of the different matura-
tion stages was quite similar among the 17 normal bone marrow
populations used in this work (see Table I). The percentage of
segmented mature neutrophils was usually 
 
 
 
10%. The purified
mixed neutrophilic population was scarcely contaminated (
 
 
 
3%) 
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with CD34
 
 
 
 progenitor cells, CD7
 
 
 
 lymphoid cells, CD36
 
 
 
 ery-
throid cells, and CD14
 
 
 
 monocytes.
 
Cell Cultures. 
 
Human immature and mature neutrophils
were cultured at 10
 
6
 
/ml in complete culture medium (RPMI
1640 containing 10% FCS) and, where indicated, treated with 50
ng/ml GM-CSF, 25 ng/ml G-CSF, or 500 ng/ml IL-3. Survivin
antisense oligonucleotides (as) or survivin mismatch control oli-
gonucleotides (ms) were used at the indicated concentrations.
When applied in combination with cytokines, the oligonucle-
otides were given 2 h before addition of cytokines.
 
Determination of Cell Death and Apoptosis. 
 
Cell death was as-
sessed at the indicated times by uptake of 1 
 
 
 
M ethidium bro-
mide and flow cytometric analysis (FACS Calibur™; references
21, 22). To determine whether cell death was due to apoptosis,
redistribution of phosphatidylserine in the absence of propidium
iodide uptake was measured by flow cytometry (22). Neutrophil
apoptosis was also assessed by oligonucleosomal DNA fragmenta-
tion (23, 24).
 
Immunoblotting. 
 
Gel electrophoresis and immunoblotting
were performed as described previously (24). In brief, after elec-
trotransfer of the separated proteins, the filters were incubated
overnight with antisurvivin (1/1,000), anti-IAP-2 (1/666), anti-
NAIP (1/1,000), anti-XIAP (1/250), anti–IAP-1 (1/333), anti–
Mcl-1 (1/1,000), or anti–caspase-3 (1/1,000) Abs at 4
 
 
 
C in TBS/
0.1% Tween 20/3% nonfat dry milk. The final concentrations of
the primary Abs ranged between 1 and 3 
 
 
 
g/ml. 20 ng of puri-
fied full-length recombinant human survivin (R&D Systems) was
used as positive control for antisurvivin immunoblotting. For
Figure 1. Purification of immature bone marrow
neutrophils. (A) After a Percoll gradient isolation, neu-
trophils were negatively selected. The resulting neutro-
phil populations were CD7 and CD36 negative. The
figure also demonstrates the positively selected cells
(right) that were analyzed to further control the purifi-
cation process. (B) The isolated CD7 CD34 CD36 
cells were MPO positive ( 97%) and contained a mix
of mostly immature neutrophils at different maturation
stages as assessed by immunophenotyping and mor-
phology (see Table I).
Figure 2. Delayed spontaneous apoptosis in immature bone
marrow neutrophils compared with mature blood neutrophils.
(A) Viability assay in the absence of survival and death factors.
Each value represents mean   SEM calculated from 3–16 (im-
mature cells) and 4–22 (mature cells) independent experi-
ments, respectively. (B) Phosphatidylserine redistribution (left)
and DNA fragmentation (right) assays. Mature cells (top) were
analyzed after 20-h cultures and immature cells (bottom) were
analyzed after 72-h cultures. The results are representative of
three independent experiments performed in both cell popula-
tions. (C) Caspase-3 is rapidly processed in mature, but not in
immature, neutrophils. In mature cells, a 20-kD fragment is
usually seen in neutrophils cultured for 4 h. The enzymatically
active 17-kD fragment is regularly detected in 8-h neutrophil
cultures. In immature cells, small amounts of the 17-kD frag-
ment are frequently seen, suggesting baseline caspase-3 activity
in these cells in the absence of apoptosis. Filters were reprobed
with an anti-GAPDH or anti– -actin mAb to ensure equal
loading of the gels. 
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loading controls, stripped filters were incubated with anti–
 
 
 
-actin
(1/10,000) or anti-GAPDH (1/2,000) mAbs. Filters were washed
in TBS/0.1% Tween 20 for 30 min and incubated with the
appropriate HRP-conjugated secondary Ab (Amersham Bio-
sciences) in TBS/0.1% Tween 20/5% nonfat dry milk for 1 h.
Filters were developed by an ECL technique (ECL-Kit; Amer-
sham Biosciences) according to the manufacturer’s instructions.
 
Densitometry Analysis. 
 
In some experiments, protein expres-
sion levels were analyzed by densitometry (24). OD of survivin,
XIAP, and Mcl-1 bands divided by the OD of the corresponding
 
 
 
-actin band are expressed as percentage of OD (protein of inter-
est)/OD (
 
 
 
-actin) of freshly isolated neutrophils that was defined
as 100%.
 
Real-Time PCR. 
 
10
 
7 
 
neutrophils were washed with PBS,
and total cellular RNA was isolated according to the RNeasy
protocol (QIAGEN), which includes DNase digestion. RNA
was reverse transcribed with the first strand cDNA synthesis kit
(Amersham Biosciences) by using random hexanucleotides ac-
cording to the manufacturer’s instructions. Specific real-time
monitoring of PCR amplification of survivin cDNA was per-
formed with a 1/100 dilution of neutrophil cDNA using the S2
primers and probe as described previously (13). Quantification of
survivin mRNA levels was performed using ribosomal RNA as
internal standard for all samples. For comparison, survivin expres-
sion in A549 lung cancer cells was quantified and taken as a 100%
reference value.
 
Enzymatic Caspase Assay. 
 
2.5 
 
 
 
 10
 
6
 
 neutrophils were cul-
tured in the presence or absence of 50 ng/ml GM-CSF, 25 ng/
ml G-CSF, antisense, or mismatch survivin oligonucleotides at
the indicated concentrations for 10 h, washed with cold PBS, and
subsequently lysed in 50 
 
 
 
l of cell lysis buffer (50 mM Hepes, pH
7.4/0.1% Chaps/5 mM DTT/0.1 mM EDTA) using a Teflon
glass homogenizer (VWR International) on ice for 10 min. After
a 10-min centrifugation step at 10,000
 
 
 
g
 
 at 4
 
 
 
C, an aliquot of the
supernatant was saved for caspase-3 immunoblotting, and cas-
pase-3–like activity was measured in 10 
 
 
 
l supernatants as enzy-
matic conversion of the colorimetric substrate Ac-DEVD-pNA
at 405 nm according to the manufacturer’s instructions (Quan-
tiZyme caspase-3 cellular activity assay kit; BIOMOL Research
Laboratories, Inc.).
 
Confocal Laser Scanning Microscopy. 
 
10
 
6
 
 cells/ml cytospins
were made from freshly purified cells on noncoated slides. Cells
were fixed in 4% paraformaldehyde at room temperature for 10
min and washed three times in PBS, pH 7.4. Permeabilization of
cells was performed with 0.05% saponin in buffer A (3% BSA in
PBS) at room temperature for 5 min and with acetone at 
 
 
 
20
 
 
 
C
for 15 min. To prevent nonspecific binding, slides were incu-
bated in blocking buffer (25% human immunoglobulins, 25%
 
Table I.
 
Relative Cellular Distribution of Purified Bone Marrow Neutrophils
 
No.
CD15
 
low
 
CD16
 
 
 
CD11b
 
 
 
(myeloblasts)
 
a
 
CD15
 
 
 
CD16
 
 
 
CD11b
 
 
 
(promyelocytes)
 
a
 
CD15
 
 
 
CD16
 
 
 
CD11b
 
low
 
(early myelocytes)
 
a
 
CD15
 
 
 
CD16
 
 
 
CD11b
 
 
 
(myelocytes)
 
a
 
CD15
 
 
 
CD16
 
low
 
CD11b
 
 
 
(metamyelocytes
and band cells)
 
a
 
CD15
 
 
 
CD16
 
 
 
CD11b
 
 
 
(mature neutrophils)
 
a
 
%% % %% %
 
1 5 10 43 22 14 6
22 8 9 2 0 5 3 5 3
3 11 18 32 6 30 3
4 21 21 42 2 11 3
5 17 4 7 2 53 17
67 4 2 5 2 3 3 2 9
7 9 21 38 18 12 2
89 6 4 8 1 4 2 0 3
9 15 13 12 2 43 15
10 5 6 22 4 34 29
11 19 11 26 10 23 11
12 26 27 25 1 20 1
13 16 12 26 5 32 9
14 12 3 15 3 59 8
15 24 2 21 11 39 3
16 7 4 23 13 47 6
17 13 1 10 16 45 15
mean (SEM) 14.4 (1.8) 10.1 (1.9) 25.6 (2.9) 9.2 (1.8) 32.3 (3.5) 8.4 (1.8)
 
a
 
The majority of the cells represent the indicated cell type. However, some overlap between different maturation stages can occur. For instance,
some early myelocytes are also present within the subpopulation indicated as “promyelocytes,” and metamyelocytes are usually seen in the subpop-
ulation defined as “myelocytes.” 
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normal goat serum, 25% normal donkey serum, and 25% BSA) at
room temperature for 1 h. Indirect immunostainings of CD15,
survivin, and caspase-3 were performed at room temperature for
1 h by using the following primary Abs: anti-CD15 mAb (1/20;
diluted in buffer A), rabbit antisurvivin polyclonal Ab (1/50), and
anti–caspase-3 mAb (1/50). Mouse and rabbit control antibod-
ies, respectively, were used at the same concentrations in each
experiment.
Immunofluorescent stainings were also performed on 5-
 
 
 
m-
thick paraformaldehyde-fixed paraffin-embedded tissue sections
from CF, appendicitis, and ulcerative colitis patients. Slides were
dried at 52
 
 
 
C for 2 h and deparaffinized using NeoClear Solution
(Merck), ethanol (100, 90, 80, 60, and 40%), and water at room
temperature. After microwave treatment in TE-buffer (10 mM
Tris, pH 8.0, and 1 mM EDTA), slides were washed in water,
blocked, and stained with primary Ab as aforementioned.
After incubation with primary Ab, cells and tissues, respec-
tively, were incubated with appropriate TRITC- and FITC-con-
jugated secondary Abs (1/100) in the dark at room temperature
for 1 h. The antifading agent Mowiol (Calbiochem) was added.
Slides were covered by coverslips and analyzed by confocal laser
scanning microscopy (LSM models 410 and 510; Carl Zeiss Mi-
croImaging, Inc.) equipped with Ar and HeNe lasers.
 
Immunohistochemistry. 
 
Aside from immunofluorescence anal-
ysis, survivin expression on tissue neutrophils was also analyzed
by regular immunohistochemistry on paraffin-embedded tissue
sections from appendicitis patients according to previously estab-
lished protocols with slight modifications (25, 26). In brief, sec-
tions were deparaffinized, and a subsequent antigen retrieval
treatment was performed. Staining with antisurvivin (1/50) was
performed using EnVision
 
 
 
System peroxidase kit (AEC; Dako-
Cytomation). A rabbit control Ab was used at the same con-
centration as a negative control. Binding of the primary Ab was
detected by a goat anti–rabbit Ab that was available in the
kit.  Sections were slightly counterstained with hematoxylin,
mounted, and examined under a microscope (Axiovert model 35;
Carl Zeiss MicroImaging, Inc.) at original magnifications (400
and 1,000).
 
Proliferation Assays. 
 
Proliferation of mature and immature
neutrophils (106/ml) was analyzed in the presence and absence of
GM-CSF and G-CSF, respectively. PBMCs were used as con-
trols. PBMCs were stimulated with 10  g/ml PHA and 5  g/ml
anti-CD3 mAb, respectively. Total culture times were 48 h (ma-
ture neutrophils and PBMCs) and 72 h (immature neutrophils).
Pulsing the cells with 1  Ci/ml (methyl-[3H]thymidine; Hart-
mann Analytic) was performed for 16 h and its incorporation was
measured by using a liquid scintillation counter (Wallac ADL).
Statistical Analysis.  An analysis of variance test and Student’s
t test were used to compare mean levels. P   0.05 was considered
statistically significant. Mean levels are presented together with
SEM. In the antisense oligonucleotide experiments, antisense and
mismatch survivin-treated cells were compared at the indicated
concentrations.
Results
Spontaneous Apoptosis Is Largely Delayed in Immature Com-
pared with Mature Neutrophils.  Purification of immature
neutrophils from morphologically normal human bone
marrow aspirates yielded a pure population of CD34 
CD36 CD7 , but also MPO positive cells (Fig. 1,  97%).
However, the cell population contained a mix of neutrophils
representing different maturation stages (Table I). When cul-
turing these mostly immature cells, we observed that they
did not rapidly undergo cell death (Fig. 2 A) and apoptosis
(Fig. 2 B) as seen in mature neutrophils. Because caspase-3
has been described as a key effector caspase in neutrophil
apoptosis (27–29), we measured caspase-3 cleavage by im-
munoblotting. Both freshly purified immature and mature
neutrophils contained significant amounts of procaspase-3
(Fig. 2 C). However, the active 17-kD fragment was not de-
tectable in the immature population. Culturing the mature
cells was associated with a partial cleavage of procaspase-3
and in the appearance of the p17 fragment usually after 4–8 h
of culture. At later time points, cleavage of procaspase-3
continued until the molecule was no longer detectable. In
contrast, culturing of immature cells up to 72 h did not result
in cleavage of procaspase-3 (Fig. 2 C). Together, these data
Figure 3. Expression of IAP family members in freshly purified imma-
ture and mature neutrophils. (A) Immunoblotting. Mature neutrophils
expressed detectable levels of XIAP, IAP-1, IAP-2, and survivin. NAIP
was often not detectable. Immature neutrophils expressed large amounts
of survivin. Filters were reprobed with anti-GAPDH or anti– -actin
mAbs to ensure equal loading of the gels. For both immature and mature
neutrophil populations, results from three different donors are shown
(1–3). (B) Confocal microscopy. Survivin was readily detected in immature,
but not in mature, neutrophils. Survivin was localized in both nucleus
and cytoplasm of immature cells. Caspase-3 was expressed in the cyto-
plasm of both immature and mature neutrophils. Interestingly, myelo-
blasts (white arrows) did not express detectable levels of caspase-3. Bars,
10  m. The results are representative of five independent experiments.Survivin Blocks Neutrophil Apoptosis 1348
suggest that immature neutrophils have much lower cas-
pase-3 activity compared with mature neutrophils, resulting
in prolonged in vitro survival.
Survivin Expression Is Lost During Neutrophil Differentia-
tion.  The antiapoptotic effects of members of the IAP
family have often been associated with decreased enzymatic
caspase activities (1, 2). Because caspase-3 did not demon-
strate evidence for high activity in immature neutrophils,
we hypothesized that specific IAPs are involved in the inhi-
bition of nascent active caspases in these cells. Expression of
IAPs was investigated by immunoblotting (Fig. 3 A). XIAP
levels were increased in two out of three investigated im-
mature neutrophil populations compared with mature
blood neutrophils. However, the most impressive differ-
ence was seen in the levels of survivin, which were dramat-
ically increased in immature compared with mature cells.
In contrast, levels of IAP-1, IAP-2, and NAIP did not
show consistent differences between the two cell popu-
lations. Immunofluorescence and laser scan microscopic
analysis confirmed that survivin was highly expressed in
immature neutrophils, but not in mature neutrophils from
normal individuals, and was detectable both in the nucleus
Figure 4. Survivin levels are markedly increased in mature neutrophils
exposed to survival factors in vitro and in neutrophils from patients with
CF. (A) Immunoblotting. Levels of survivin in neutrophils were increased
by culturing normal control neutrophils in the presence of GM-CSF or
G-CSF for 12 h. Moreover, freshly purified neutrophils from CF patients
(n   4) showed strongly increased survivin protein levels compared with
control blood neutrophils. 20 ng purified recombinant survivin served as
a positive control. The filter was reprobed with an anti– -actin mAb to
ensure equal loading of the gel. (B) Real-time PCR. The lung cancer cell
line A549 served as a standard (100%). Neutrophils from patients with CF
contained increased amounts of survivin mRNA compared with normal
neutrophils (left). The increase in survivin mRNA was mimicked by ad-
dition of GM-CSF or G-CSF to normal control neutrophils in vitro
(right). Values are means   SEM of three independent experiments. *,
P   0.05; ***, P   0.001. (C) Proliferation assay. Freshly purified blood
neutrophils from normal donors or CF patients did not demonstrate evi-
dence for cell proliferation. The same was true for G-CSF– or GM-CSF–
stimulated normal mature neutrophils. In contrast, immature neutrophils
demonstrated significant proliferation, which was inducible by both GM-
CSF and G-CSF. Pan–T cell–stimulated PBMCs were used as positive
controls. Results of four independent experiments are shown for each cell
population.
Figure 5. Survivin expression in mature neutrophils under in vivo in-
flammatory conditions. (A) Immunohistochemistry. Cells morphologi-
cally representing neutrophils expressed survivin in tissue sections from
patients with appendicitis. A control antibody did not stain the cells. (B).
Confocal microscopy. Tissue neutrophils from patients with CF (n   3),
ulcerative colitis (n   3), and appendicitis (n   3) demonstrated evidence
for survivin expression. Neutrophils were specifically detected using an
anti-CD15 mAb. Note that in ulcerative colitis and appendicitis, some
neutrophils were survivin negative (red cells in the overlay panel). Bars,
10  m.Altznauer et al. 1349
and the cytoplasm (Fig. 3 B). Interestingly, caspase-3 was
not expressed at early stages of neutrophil maturation (my-
eloblast; Fig. 3 B, arrows).
Survivin Expression Is Reinduced in Inflammation.  Dur-
ing maturation, neutrophils are exposed to high levels of
cytokines in the bone marrow. Some of these cytokines,
such as GM-CSF and G-CSF, are also elevated in bacterial
infectious diseases (19). Interestingly, mature neutrophils
derived from the blood of patients suffering from CF ex-
hibited significantly higher levels of survivin compared
with normal blood neutrophils as assessed by immunoblot-
ting. Moreover, GM-CSF and G-CSF increased survivin
expression of normal neutrophils upon in vitro stimulation
for 12 h (Fig. 4 A). Elevated survivin protein levels corre-
lated with increased mRNA expression as assessed by real-
time PCR analysis. The mean mRNA levels in peripheral
blood neutrophils from patients with CF were increased
 10-fold compared with control cells. Moreover, GM-
CSF and G-CSF dramatically increased survivin mRNA
expression in normal mature neutrophils within 4 h (Fig. 4
B). Both cytokine-stimulated normal neutrophils and CF
neutrophils did not demonstrate any evidence for cell pro-
liferation as assessed by [3H]thymidine incorporation assays
(Fig. 4 C) and DNA analysis (not depicted). In contrast
with mature neutrophils, immature neutrophils demon-
strated significant baseline proliferation and proliferation
was inducible by both GM-CSF and G-CSF.
To demonstrate survivin expression in neutrophils under
in vivo conditions, we analyzed neutrophils in tissue sec-
tions of patients with three distinct inflammatory diseases.
As assessed by immunohistochemistry, most neutrophils in
the affected intestinal mucosa from patients with acute ap-
pendicitis stained positively using an antisurvivin antibody
(Fig. 5 A). To more specifically measure protein expression
in neutrophils, we also performed double immunofluores-
cence analysis. Infiltrating neutrophils were identified using
an anti-CD15 mAb. In the lungs of CF patients, practically
all neutrophils expressed survivin. In the intestine of ulcer-
ative colitis patients, we counted  90% survivin-express-
ing neutrophils. In appendicitis,  75% of the infiltrating
neutrophils were survivin positive (Fig. 5 B). These data
suggest that high levels of survivin are not restricted to im-
mature neutrophils and that mature neutrophils are able
to reinduce high levels of survivin expression upon GM-
CSF and/or G-CSF exposure under in vitro and in vivo
conditions.
Elevated levels of survivin in peripheral blood neutro-
phils from patients with CF were confirmed by immuno-
fluorescence and laser scan microscopy demonstrating
that almost all neutrophils expressed survivin, predomi-
nantly in the cytoplasm (Fig. 6 A). Increased survivin
levels in CF neutrophils correlated with decreased cas-
pase-3–like DEVDase in 10-h neutrophil cultures (Fig.
6 B). Moreover, caspase-3–like DEVDase activity was
much less in neutrophils stimulated with G-CSF or
GM-CSF in vitro.
Survivin Delays Apoptosis in a Cell Cycle–independent Man-
ner. The role of survivin as an antiapoptotic protein is still a
matter of debate. Some authors concluded that survivin is
less important for apoptosis regulation (30), whereas others
suggested a significant role of this molecule in protecting
cells from apoptosis in a cell cycle–dependent manner (3,
4). Mature neutrophils are terminally differentiated cells
unable to proliferate (Fig. 4 C). Thus, this system not only
represents an ideal tool to answer the question whether in-
creased survivin levels prevent or reduce apoptosis, it also
provides the unique possibility to test whether survivin
exhibits antiapoptotic activity in a cell cycle–independent
manner and beyond the G2-M checkpoint (5). The role of
survivin in the apoptosis regulation of mature neutrophils
was characterized by preventing its cytokine-mediated ex-
pression. Specific antisense but not mismatch oligonucle-
otides blocked the production of high levels of survivin
mRNA (Fig. 7 A) and protein (Fig. 7 B) upon GM-CSF or
Figure 6. Survivin is predominantly localized in the cytoplasm of ma-
ture CF neutrophils and associated with low caspase-3 enzymatic activity.
(A) Confocal microscopy. Survivin was readily detected in CF blood
neutrophils where it is mostly localized in the cytoplasm. Bars, 10  m.
Three independent experiments are presented. (B) Caspase-3 activity as-
say. Neutrophils were analyzed after a 10-h culture period. Caspase-3 ac-
tivity was much lower in CF compared with control neutrophils. In addi-
tion, when normal neutrophils were cultured in the presence of GM-CSF
or G-CSF, significantly lower caspase-3 activity levels were measured.
Values are means   SEM of eleven (C), three (CF), four (G-CSF), and
two (GM-CSF) independent experiments. ***, P   0.001.Survivin Blocks Neutrophil Apoptosis 1350
Figure 7. Antisense oligonucleotide treat-
ment specifically prevents increases in survivin
gene expression and antiapoptosis mediated by
GM-CSF or G-CSF in mature neutrophils. (A)
Real-time PCR. The lung cancer cell line A549 served as a standard
(100%). Oligonucleotides (as and ms) had no effect on survivin mRNA
expression in the absence of survival cytokines after a 4-h transfection
period (top). Survivin-antisense (as), in contrast with mismatch control
oligonucleotides (ms), prevented increases in survivin mRNA expres-
sion upon GM-CSF (middle) or G-CSF (bottom) stimulation in a dose-
dependent manner. Values are means   SEM of three independent ex-
periments. *, P   0.05; **, P   0.01; ***, P   0.001. (B) Immunoblotting.
Protein expression of survivin in normal neutrophils was not affected by
incubation with as or ms (not depicted). However, survivin-as, in con-
trast with ms, partially (GM-CSF) or completely (G-CSF) prevented
cytokine-induced increases in survivin expression. To demonstrate the
specificity of the survivin-as effects, we also measured XIAP and Mcl-1
levels in the experiments using G-CSF. The filters were reprobed with
an anti– -actin mAb to ensure equal loading of the gels, and results of
the densitometry analysis in terms of percentage are presented below the
immunoblots. Results are representative of three independent experi-
ments. (C) DNA fragmentation assay. Targeting survivin expression by
survivin-as increased spontaneous apoptosis (left). GM-CSF (middle)
and G-CSF (right) prevented apoptosis, and survivin-as blocked cyto-
kine-mediated survival in a dose-dependent manner. Neutrophils were
cultured for 10 h. Values are means   SEM of four independent ex-
periments. *, P   0.05; **, P   0.01; ***, P   0.001. (D) Viability assay.
Neutrophils from survivin /  mice demonstrated reduced IL-3–medi-
ated survival. Neutrophils were isolated from blood and cultured in the
presence of IL-3 for 24 h before viability was measured. No difference
in spontaneous cell death was noticed between survivin /  and
survivin /  mice (not depicted). Values are means   SEM of four inde-
pendent experiments. *, P   0.05.Altznauer et al. 1351
G-CSF stimulation. Although antisense oligonucleotides
partially inhibited GM-CSF–induced survivin protein ex-
pression (Fig. 7 B, top), the effects of G-CSF were com-
pletely blocked in this cell culture system at a dose of 5.0
 M (Fig. 7 B, bottom). To further prove the specificity of
the survivin antisense oligonucleotides, we also analyzed
XIAP and Mcl-1 protein levels. Both proteins were se-
lected because of their potential antiapoptotic activities in
neutrophils (31, 32). Although Mcl-1 levels were slightly
affected at 5.0  M antisense, no significant effects on the
expression levels of these two control proteins were ob-
served (Fig. 7 B, bottom). This suggests that reduction of
survivin levels was an antisense-specific effect and not due
to off-target effects mediated by nonantisense related toxic-
ity of the oligonucleotides.
Survivin antisense but not mismatch oligonucleotides
significantly increased spontaneous apoptosis of mature
neutrophils in a dose-dependent manner as assessed by the
formation of oligonucleosomal DNA fragments (Fig. 7 C).
At very high concentrations ( 10  M), mismatch oligo-
nucleotide treatment was also associated with additional
DNA fragmentation, indicating nonspecific toxicity. GM-
CSF and G-CSF–treated neutrophils showed a higher con-
tent of normal diploid DNA compared with untreated
cells, indicating less apoptosis. Survivin antisense oligonu-
cleotides blocked GM-CSF and G-CSF–mediated antiap-
optotic effects in a statistically significant and dose-depen-
dent manner. Compared with the nonspecific effect of the
mismatch control oligonucleotides and in agreement with
the protein expression data (Fig. 7 B), antisense concentra-
tions of 2.5  M (for GM-CSF) and 5.0  M (for G-CSF)
were found to be optimal for neutralizing the effects of the
survival factors.
To confirm the data obtained by lowering survivin pro-
tein expression using antisense oligonucleotides, we puri-
fied blood neutrophils from survivin /  mice (20). These
mice express  50% of normal survivin levels and demon-
strated evidence for increased caspase activation in hepato-
cytes. Purified neutrophils from survivin /  mice did not
exhibit an accelerated cell death in vitro when compared
with normal neutrophils. However, the IL-3–mediated an-
tideath effect, observed in normal neutrophils, was signifi-
cantly reduced in the genetically modified mice (Fig. 7 D).
We also monitored caspase-3 activation as a consequence
of survival factor and/or survivin antisense treatment.
Freshly isolated neutrophils contained procaspase-3, but no
active 17-kD fragment (Fig. 8 A). Culturing of cells for 10 h
resulted in decreased amounts of procaspase-3 and in the
appearance of the 17-kD form. Antisense oligonucleotide
treatment had no additional effects. GM-CSF delayed the
proteolysis of procaspase-3. Similar effects were seen using
G-CSF (reference 33 and unpublished data). This effect of
the survival factors on procaspase-3 processing was com-
pletely abrogated by optimal concentrations of antisense
but not mismatch oligonucleotides. Furthermore, caspase-
3–like DEVDase activity was suppressed by G-CSF and
GM-CSF in 10-h cultures, and this was also abolished by
antisense but not mismatch oligonucleotides (Fig. 8 B).
Together, to counteract G-CSF–mediated protection of
procaspase-3 and inhibition of caspase-3 activity, 5.0  M
antisense oligonucleotides were required, whereas 2.5  M
were sufficient to abolish the GM-CSF effect. These data
correlated well with the levels of survivin protein expres-
sion (Fig. 7 B) and the induction of apoptosis (Fig. 7 C).
Discussion
In contrast with earlier studies that propagated survivin
as a tumor-specific target, recent work has unveiled sur-
vivin expression also in normal adult tissues, including the
proliferating fraction of CD34  cells in the bone marrow
(34). In this work, we investigated the role of survivin as a
Figure 8. Survivin-antisense treatment abolishes the inhibitory effect of
survival cytokines on caspase-3 activation in mature neutrophils. (A) Im-
munoblotting. Neutrophils cultured in the presence of GM-CSF for 10 h
maintained greater amounts of the caspase-3 proform and had decreased
levels of the 17-kD fragment compared with untreated or oligonucle-
otide-treated cells. Survivin-antisense treatment (as), but not mismatch
control oligonucleotides (ms), increased caspase-3 processing in the pres-
ence of GM-CSF in a dose-dependent manner. The same results were
obtained in two additional experiments. (B) Caspase-3 activity assay. In-
creased enzymatic activity was detectable in neutrophils undergoing
spontaneous apoptosis compared with GM-CSF– or G-CSF–treated cells.
Survivin-as but not ms increased caspase-3–like enzymatic activity in the
presence of GM-CSF or G-CSF in a dose-dependent manner. Results of
two independent experiments are shown (circles, experiment 1; triangles,
experiment 2).Survivin Blocks Neutrophil Apoptosis 1352
regulator of apoptosis signaling in neutrophils and report
the following new findings. First, immature neutrophils
express large amounts of survivin protein compared with
terminally differentiated cells, which express no or little
survivin. Second, elevated survivin levels in mature neu-
trophils are observed in active inflammatory diseases,
such as acute appendicitis, ulcerative colitis, and CF.
Thus, increased expression of survivin is a common phe-
nomenon of inflammation and not restricted to cancer or
other proliferating cells. Third, GM-CSF and G-CSF in-
duce survivin gene expression in mature neutrophils in a
cell cycle–independent manner. Last, survivin is able to
function as an antiapoptotic protein beyond the G2-M
checkpoint.
Survivin is a member of the IAP family, which seems to
constitute a final false-safe mechanism to prevent intracel-
lular damage due to premature caspase activation. For in-
stance, it has been reported that XIAP, another member
of the IAP family (1), prevents death receptor–mediated
apoptosis by inhibition of caspase-3 (35). In these cells, it
appears that Bid-mediated release of Smac from mitochon-
dria is required to neutralize the IAP function to activate
caspase-3 (36). Further support for the potency of IAPs to
prevent premature apoptosis is provided by the observation
that in some cells, mitochondria can be activated to release
cytochrome c, but do not induce apoptosis (37). Thus, mi-
tochondrial and caspase activation do not necessarily repre-
sent a “point of no return” in response to a death stimulus.
XIAP appears to be the most potent inhibitor of active
caspases compared with other members of the IAP family
(38). The expression of XIAP (31), as well as of IAP-1 (39)
and IAP-2 (39), has been reported previously in mature
neutrophils. In this work, we obtained evidence for the ex-
pression of XIAP, IAP-1, IAP-2, and survivin in these
cells. XIAP and survivin were found to be inducible by
G-CSF. Because XIAP expression was not always increased
in immature compared with mature neutrophils, we fo-
cused our investigations in this work on the cytoprotective
role of survivin.
Survivin expression seems to be a matter of active regu-
lation in neutrophils during differentiation and inflamma-
tion. Reduced expression in mature compared with imma-
ture neutrophils was associated with caspase-3 activation
and spontaneous apoptosis. Moreover, antisense-mediated
inhibition of survivin expression prevented the antiapop-
totic effect of GM-CSF and G-CSF in human neutrophils.
A similar antiapoptosis block was observed in neutrophils
from survivin /  mice. Therefore, although survival cyto-
kines may also increase the ratio between anti- and proap-
optotic Bcl-2 family members (32, 40), their ability to
increase survivin levels seems to be crucial for delayed neu-
trophil apoptosis.
A role of survivin in the regulation of apoptosis has pre-
viously been suggested in other cell types, particularly in
tumor cells (12). The protective effect of survivin was re-
ported to depend on its localization at the mitotic spindle
and hence to be cell cycle–dependent (3–5). Moreover,
survivin expression was seen at the G2-M boundary where
its inhibition was accompanied by cell cycle defects. In ad-
dition, the embryonic lethal phenotype of survivin /  mice
implicated a key role for survivin in mitosis (40). The con-
cept that survivin acts as an IAP has also been challenged by
other papers in which a role in cytokinesis was suggested
(41–43). Here, we demonstrate that survivin expression is
not necessarily linked to the cell cycle, and that it indeed
acts as an IAP without the requirement of spindle associa-
tion. The notion that survivin expression is not limited to
the G2-M phase is supported by earlier findings in CD34 
cells, which express survivin in all phases of the cell cycle
(34, 44). Because the expression of survivin is highly regu-
lated by survival factors and subject to rapid changes, it
appears that survivin plays a key role in modulating the ap-
optotic threshold in neutrophils according to the bio-
logical requirements in a given physiologic or pathologic
situation.
Another important finding of this work is that high sur-
vivin levels are not restricted to embryonic tissues and tu-
mors, and particularly that inflammatory diseases are also
associated with increased survivin levels. In conjunction
with other papers describing its expression in hematopoi-
etic progenitor cells (34, 44, 45) and T cells (46), this is of
paramount importance and questions the value of survivin
as a therapeutic target in cancer (12), due to the profound
myelo- and immunosuppressive effects that might be ex-
pected from this treatment.
In summary, this paper demonstrates the importance of
survivin in the regulation of neutrophil apoptosis and con-
firms its role as an antiapoptotic protein. Elevated survivin
levels are present in neutrophils during normal differentia-
tion in the bone marrow and represent a physiologic re-
sponse in mature terminally differentiated cells under in-
flammatory conditions. Therefore, survivin might represent
a novel target for antiinflammatory therapy. Moreover, and
in contrast with previous papers, we demonstrate that sur-
vivin expression and its function as an IAP does not require
cell cycle progression and mitotic spindle formation. Fur-
ther analyses are needed to clarify whether additional sig-
nals exist that regulate survivin expression in primary cells
and to elucidate the molecular mechanisms underlying the
regulation of survivin expression in various biological
systems.
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